Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: inhalation

Currently viewing:

Administrative data

Endpoint:
sub-chronic toxicity: inhalation
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Acceptable, well-documented study report similar or equivalent to OECD 413 TG under GLP conditions performed on an analogue substance.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1987
Report date:
1987

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
GLP compliance:
yes (incl. QA statement)
Limit test:
yes

Test material

Constituent 1
Reference substance name:
Naphtha (petroleum), light catalytic cracked
EC Number:
265-056-2
EC Name:
Naphtha (petroleum), light catalytic cracked
Cas Number:
64741-55-5
IUPAC Name:
Naphtha (petroleum), light catalytic cracked
Constituent 2
Reference substance name:
light catalytic cracked naphtha
IUPAC Name:
light catalytic cracked naphtha

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female

Administration / exposure

Route of administration:
inhalation: vapour
Type of inhalation exposure:
whole body
Vehicle:
other: unchanged (no vehicle)
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Scott Model 216 THA
Duration of treatment / exposure:
13 weeks
Frequency of treatment:
6 hours per day five days per week
Doses / concentrationsopen allclose all
Remarks:
Doses / Concentrations:
7248 mg/m3
Basis:
analytical conc.
Remarks:
Doses / Concentrations:
12528 mg/m3
Basis:
analytical conc.
Remarks:
Doses / Concentrations:
21792 mg/m3
Basis:
analytical conc.
No. of animals per sex per dose:
20 males and 20 females per dose
Control animals:
yes, sham-exposed

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Mortality:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
no effects observed
Clinical biochemistry findings:
no effects observed
Urinalysis findings:
no effects observed
Behaviour (functional findings):
not specified
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Gross pathological findings:
no effects observed
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Histopathological findings: neoplastic:
effects observed, treatment-related
Details on results:
CLINICAL SIGNS AND MORTALITY: High-dose males and females exhibited red material around the nose. Other clinical signs seen did not show any treatment-related trends. All animals survived to termination of the study.

BODY WEIGHT AND WEIGHT GAIN: Statistically significant decreases in mean body weights were noted in study weeks 2 through 13 for high-dose males and during weeks 4 and 5 for mid-dose males, when compared with control males. Group mean body weights were similar between control and treated females.

HAEMATOLOGY: There were no differences between exposed and control animals for any of the hematologic parameters which could be ascribed to the test material exposures.

CLINICAL CHEMISTRY: There were no differences between exposed and control animals for any of the biochemistry parameters which could be ascribed to the test material exposures.

URINALYSIS: There were a few statistically significant differences between exposed and control animals, but since all values were within the normal range, none of the differences were considered exposure related.

ORGAN WEIGHTS: At the terminal sacrifice, test article related organ weight changes were observed in the liver and kidney of male and female rats.

GROSS PATHOLOGY: No test article related macroscopic changes were observed in any of the male and female rats that were sacrificed after a 13 weeks exposure period.

HISTOPATHOLOGY: NON-NEOPLASTIC: There were test article related changes observed in the livers of male anf female rats and in the kidneys of male rats from the high-dose level.

HISTOPATHOLOGY: NEOPLASTIC: The liver change consisted of centrilobular hepatocellular hypertrophy involving scatted lobules. The liver cell enlargement was minimal. The incidence was slightly higher in male rats than in females (10/20 in males and 5/20 in females). The kidney changes in males consisted of: (a) granular casts within tubules located in the outer zone of the medulla, (b) tubular degeneration and regeneration, particularly in the proximal convoluted tubules, and (c) an increased incidence of chronic interstitial inflammatory recation. The severity of these changes varied from trace to mild and the distribution was multifocal. Most of the tubules that contained the granular casts appeared dilated with some degree of flattening and/or pressure necrosis of the lining epithelia. Degeneration of tubular epithelium was minimal, but regeneration was comparatively more prominent. Around some of these tubules there was infiltration with chronic inflammatory cells, primarily mononuclear cells. These changes occurred in other areas as well.

Effect levels

open allclose all
Dose descriptor:
NOAEC
Effect level:
ca. 21 792 mg/m³ air (analytical)
Sex:
female
Basis for effect level:
clinical signs
organ weights and organ / body weight ratios
Dose descriptor:
NOAEC
Effect level:
ca. 12 528 mg/m³ air (analytical)
Sex:
male
Basis for effect level:
body weight and weight gain
clinical signs
organ weights and organ / body weight ratios

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Conclusions:
Exposure to light catalytically cracked naphtha (API 81-03) for 13 weeks produced mild but significant toxic responses in males, depressed body weights and typical hydrocarbon induced nephropathy. Female rats were essentially unaffected by the test material. Therefore, the male NOAEL was determined to be 12528 mg/m3 and the female NOAEL was concluded to be 21792 mg/m3.
Executive summary:

The purpose of this study was to evaluate the subchronic toxicity of light catalytically cracked naphtha when administered to Sprague-Dawley rats by whole body inhalation exposure for thirteen consecutive weeks at the analytical concentrations of 7248 mg/m3, 12528 mg/m3, and 21792 mg/m3. Very few responses were observed in male or females rats at the high-dose with the exception of red nasal discharge. Decreased body weight gain was observed in male rats of the mid- and high-dose groups. There were no exposure-related differences for either males or females in any of the hematologic, serum biochemical or urinalysis parameters evaluated. Exposure-related increases in the liver weights of male and female rats and the kidney weights of male rats were observed. Therefore, the male NOAEL was determined to be 12528 mg/m3 and the female NOAEL was concluded to be 21792 mg/m3.